Amanda Yopp Discusses the Challenges With Treating Multiple Myeloma Patients

Article

Amanda Yopp, NP, Clinical Nurse Educator, Takeda Oncology, discusses the challenges with treating patients with multiple myeloma.

Amanda Yopp, NP, Clinical Nurse Educator, Takeda Oncology, discusses the challenges with treating patients with multiple myeloma.

Recent Videos
Man in suit standing in front of blue watercolor Oncology Nursing News backdrop
Image of a woman in front of a blue Oncology Nursing News-branded backdrop.
Related Content
light blue background with a white outline indicating blood cells

Positive Responses to Liso-Cel Observed in Relapsed/Refractory Marginal Zone Lymphoma

Ashling Wahner
February 16th 2025
Article

Lisocabtagene maraleucel demonstrated a statistically significant overall response rate in adults with relapsed/refractory marginal zone lymphoma.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Lindsay Fischer
December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Simple white line illustration of red blood cells on a yellow background

Evaluating the Risk of Second Primary Cancers After CAR T-Cell Therapy

Ashling Wahner
January 30th 2025
Article

The association of CAR T-cell therapies with second primary cancers warrants the development and examination of mitigation strategies for these toxic effects.

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Lindsay Fischer
December 1st 2023
Podcast

Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.

dark blue background with three people around a clip board

NCCN Recommends ctDNA Testing for MRD Assessment in DLBCL

Ashling Wahner
January 14th 2025
Article

NCCN guidelines now recommend ctDNA testing for MRD assessment for patients with PET-positive DLBCL after treatment.

an illustration of a bone with circles around it indicating a microscope, test tubes and prescriptions

Subcutaneous Isatuximab Non-Inferior to IV in Relapsed/Refractory Myeloma

Caroline Seymour
January 10th 2025
Article

In patients with RRMM, subcutaneous isatuximab plus Pd resulted in a non-inferior objective response rate (ORR) and comparable pre-dose concentrations at steady state compared to IV isatuximab plus Pd.